Alterations in plasma lipid profile and cardiovascular risk indicators in clinically sub-grouped psoriasis
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20190429Keywords:
Psoriasis, PASI score, Lipid parameters, Atherogenic index of plasma, Cadiac risk ratio, Atherogenic coefficientAbstract
Background: Psoriasis, a chronic skin complication been considered in the recent years by dermatologists as a systemic disease with multi organ abnormalities. Dyslipidemia commonly observed in psoriasis patients may result in cardiovascular complications hence a prompt routine cardiovascular risk evaluation is essential in these patients. A study was designed to assess plasma lipid profile as well as cardiovascular risk markers in psoriasis patients to find out the relationship between cardiovascular risk indicators and psoriasis disease severity.
Methods: Study consists of 200 subjects including 100 psoriatics. These psoriatics were sub-grouped based on their increasing PASI score into four groups.
Results: The results indicate a significant elevation in lipid parameters and in cadiac risk ratio, atherogenic index of plasma as well as atherogenic coefficient in psoriatics as compared to normal controls. Further a parallel raise has seen in these lipid parameters and risk indicators based on their increasing PASI score.
Conclusions: It can be stated from the study results that psoriatics are more affected group for cardiovascular complications and a proper evaluation of cardiovascular risk indicators in these patients is essential in preventing development of cardiovascular risk. Further the risk indicators atherogenic index of plasma and atherogenic coefficient are more promising in evaluating cardiovascular risk in psoriases patients.
References
Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Kremers HM. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol. 2009;60(3):394-401.
Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC. Lipid disturbances in psoriasis: an update. Mediators Inflamm. 2010;2010.
Chibowska M. Role of serum lipids in pseriasis. Przegl Dermatol. 1970;57(2):255-60.
Pietrzak A, Toruniowa B, Pietrzak B, Chwaluk J. Lipid profile in psoriatic patients according to sex and age. Przegl Dermatol. 1994;81(5):441-9.
Pietrzak A, Jastrzębska I, Krasowska D, Chodorowska G, Tabarkiewicz J, Tomasiewicz K, et al. Serum pancreatic lipase (EC 3.1. 1.3) activity, serum lipid profile and peripheral blood dendritic cell populations in normolipidemic males with psoriasis. J Mol Catal B Enzym. 2006;40(3-4):144-54.
Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated withlipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54(4):614-21.
Solak Tekin N, Tekin IO, Barut F, Yilmaz Sipahi E. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm. 2007;2007:78454.
Farshchian M, Zamanian A, Farshchian M, Monsef AR, Mahjub H. Serum lipid level in Iranian patients with psoriasis. J Eur Acad Dermatol Venereol. 2007;21(6):802-5.
Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al.Prevalence of metabolic syndrome in patients with psoriasis: a hospitalbased case–control study. Br J Dermatol. 2007;157(1):68-73.
Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. Dermatology. 2008;216(2):152-5.
Tam LS, Tomlinson B, Chu TW, Li M, Leung YY, Kwok LW, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls-the role of inflammation. Rheumatology (Oxford). 2008;47(5):718-23.
Ferretti G, Simonetti O, Offidani AM, Messini L, Cinti B, Marshiseppe I, et al. Changes of plasma lipids and erythrocyte membrane fluidity in psoriatic children. Pediatr Res. 1993;33(5):506-9.
Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta. 2001;303(1-2):33-9.
Akhyani M, Ehsani AH, Robati RM, Robati AM. The lipid Profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol. 2007;21(10):1330-2.
Javidi Z, Meibodi NT, Nahidi Y. Serum lipids abnormalities and psoriasis. Indian J Dermatol. 2007;52(2):89.
Amin T, Saied, E, Abdou SH. Atherosclerotic risk in psoriasis. J Pan-Arab League of Dermatol. 2005;16(2):39-45.
Bajaj DR, Mahesar SM, Devrajani BR, Iqbal MP. Lipid profile in patients with psoriasis presenting at Liaquat University Hospital Hyderabad. J Pak Med Assoc. 2009;59(8):512-5.
Reynoso-von Drateln C, Martinez-Abundis E, Balcazar- Munoz BR, Bustos-Saldana R, Gonzalez-Ortiz M. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol. 2003;48(6):882-5.
Kumari A, Gowda H. A clinical study of psoriasis and its association with serum lipid profile. metabol. 2017;10:11.
Naito HK. Coronary artery disease and disorders of lipid metabolism: Clinical chemistry theory analysis co relations. 4th ed. Kaplan LA, Peace AJ Kazmierczak SC, eds. St Louis, USA: Mosby Inc; 2003: 603.
Tietz NW. Clinical guide to laboratory tests. WB Saunders Co; 1995: 4.
Matsuzaki Y, Kawaguchi E, Morita Y, Mashige F, Ohisa S, Nakahara K.Evaluation of two kinds of reagents for direct determination of HDL-cholesterol. J Anal Bio-Sc. 1996;19:419-7.
Friedwal WT, Levy R1, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
Ikewuchi Cj, ikewuchi CC. Alteration of plasma lipid profile and atherogenic indices of cholesterol loaded rats by Tridax procumbencens Linn: Imlications for the management of obesity and cardiovascular diseases. Biokemistri. 2009;21(2):95-9.
Dobiasova M. Atherogenic index of plasma (log (triglycerides/HDL- cholesterol): Theoretical and practical implications. Clin Chem. 2004;50(7):1113-5.
Panimathi R. Rekha K, Geetha K. Total cholesterol/HDL Rasio – and individual predictor of atheroselerosis in acute coronary syndrome. Sch G App Med Sci. 2017;5(8C):3204-8.
Piskin S, Gurkok F, Ekuklu G, Senol M. Serum lipid levels in psoriasis. Yonsei Med J. 2003;44(1):24-6.
Taheri Sarvtin M, Hedayati MT, Shokohi T, HajHeydari Z. Serum lipids and lipoproteins in patients with psoriasis. Arch Iran Med. 2014;17(5):343-6.
Amer M, Galal A, Amer A. Psoriasis Severity is Affected by T the Lipid Profile in Egyptian Patients. Gynecol Obstet Sunnyvale. 2015;5(12):1-3.
Beisel WR. Metabolic response to infection. Annu Rev Med. 1975;26:9-20.
Gyulai R, Kemeny L. The immunology of psoriasis: from basic research to the bedside. Orv Hetil. 2006;147(46):2213-20.
Oppenheim JJ, Cohen S. Interleukins, lymphokines, and cytokines. InProc.3rd Int. Lymphokine Workshop. New York: Academic Press, Inc; 1983: 441-446.
Dinarello CA. Interleukin-1 and its biologically related cytokines. Adv Immunol. 1989;44:153-205.
Feingold KR, Soued M, Adi S, Staprans I, Neese R, Shigenaga J, et al. Effect of interleukin-1 on lipid metabolism in the rat. Similarities to and differences from tumor necrosis factor. Arterioscler Thromb. 1991;11(3):495-500.
Gyulai R, Kemeny L. The immunology of psoriasis: from basic research to the bedside. Orv Hetil. 2006;147(46):2213-20.
Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, et al. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Dermatol Sci. 2009;55(3):202-4.
Im SS, Yousef L, Blaschitz C, Liu JZ, Edwards RA, Young SG, et al. Linking lipid metabolism to the innate immune response in macrophages through sterol regulatory element binding protein-1a. Cell Metab. 2011;13(5):540-9.
Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, Abrishami M, Juya M, Khodaee G, et al. Atherogenic index of plasma (AIP): a marker of cardiovascular disease. Med J Islam Repub Iran. 2015;29:240.
